Cue Biopharma, Inc. Amortization of Debt Discount (Premium)
Cue Biopharma, Inc. (CUE) reported Amortization of Debt Discount (Premium) of -$212.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-03-16
- Cue Biopharma, Inc. amortization of debt discount (premium) for the quarter ending 2025-12-31 was -$30.00K.
- Cue Biopharma, Inc. amortization of debt discount (premium) for the quarter ending 2024-12-31 was $0.00.
- Cue Biopharma, Inc. amortization of debt discount (premium) for the quarter ending 2024-09-30 was $0.00.
- Cue Biopharma, Inc. amortization of debt discount (premium) for the quarter ending 2024-06-30 was $0.00.
- Cue Biopharma, Inc. amortization of debt discount (premium) for fiscal 2025 was -$212.00K.
- Cue Biopharma, Inc. amortization of debt discount (premium) for fiscal 2024 was $0.00.
- Cue Biopharma, Inc. amortization of debt discount (premium) for fiscal 2023 was -$234.00K.
- Cue Biopharma, Inc. amortization of debt discount (premium) for fiscal 2022 was -$321.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month | Amortization of Debt Discount (Premium) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$212.00K 10-K · filed 2026-03-16 | |||
| 2025-09-30 | -$182.00K 10-Q · filed 2025-11-12 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $0.00 derived: sum of 3 quarters · filed 2026-03-16 | $0.00 10-K · filed 2026-03-16 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | -$12.00K derived: sum of 4 quarters · filed 2025-03-31 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | -$12.00K derived: sum of 3 quarters · filed 2025-03-31 | -$85.00K derived: sum of 4 quarters · filed 2025-03-31 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$12.00K derived: sum of 2 quarters · filed 2025-03-31 | -$85.00K derived: sum of 3 quarters · filed 2025-03-31 | -$234.00K 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$85.00K derived: sum of 2 quarters · filed 2024-11-14 | -$234.00K 10-Q · filed 2024-11-14 | -$454.00K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$73.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$222.00K 10-Q · filed 2024-08-14 | -$442.00K derived: sum of 3 quarters · filed 2024-08-14 | -$543.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$149.00K 10-Q · filed 2024-05-09 | -$369.00K derived: sum of 2 quarters · filed 2024-05-09 | -$470.00K derived: sum of 3 quarters · filed 2024-05-09 | -$470.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | -$220.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$321.00K derived: sum of 2 quarters · filed 2024-03-28 | -$321.00K derived: sum of 3 quarters · filed 2024-03-28 | -$321.00K 10-K · filed 2024-03-28 | -$320.61K 10-K · filed 2023-03-21 |
| 2022-09-30 | -$101.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$101.00K derived: sum of 2 quarters · filed 2023-11-03 | -$101.00K 10-Q · filed 2023-11-03 | -$100.58K derived: sum of 4 quarters · filed 2023-11-03 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $419.00 derived: sum of 3 quarters · filed 2023-08-08 | $419.00 derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $419.00 derived: sum of 2 quarters · filed 2023-05-09 | $419.00 derived: sum of 3 quarters · filed 2023-05-09 | $419.00 derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $419.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $419.00 derived: sum of 2 quarters · filed 2023-03-21 | $419.00 derived: sum of 3 quarters · filed 2023-03-21 | -$4.58K 10-K · filed 2023-03-21 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | -$5.00K 10-Q · filed 2022-11-14 | $1.69K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$5.00K 10-Q · filed 2022-08-04 | $1.69K derived: sum of 3 quarters · filed 2022-08-04 | $23.69K derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$5.00K 10-Q · filed 2022-05-10 | $1.69K derived: sum of 2 quarters · filed 2022-05-10 | $23.69K derived: sum of 3 quarters · filed 2022-05-10 | ||
| 2020-12-31 | $6.69K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $28.69K derived: sum of 2 quarters · filed 2022-03-16 | $83.69K 10-K · filed 2022-03-16 | ||
| 2020-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $77.00K 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $55.00K 10-Q · filed 2021-08-09 | ||||
| 2019-12-31 | -$72.46K 10-K · filed 2021-03-09 | ||||
| 2019-06-30 | -$71.00K 10-Q · filed 2020-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |